INTRODUCTION
X-linked lymphoproliferative disease (XLP-1) is a heritable immune disorder caused by germline mutations in the SH2D1A gene, which encodes the signaling lymphocytic activation molecule (SLAM)-associated protein (SAP) (1) . SAP is a small SH2 domaincontaining adaptor primarily expressed in T, natural killer (NK), and invariant NKT (iNKT) cells (1) . XLP-1 is best recognized for the increased susceptibility of affected males to develop overwhelming lymphoproliferation after primary Epstein-Barr virus (EBV) infection (2) . Also known as fulminant infectious mononucleosis (FIM), this lymphoproliferative process is characterized by the massive accumulation of activated CD8 + T cells, which infiltrate multiple organs and inflict severe tissue damage. FIM is the most common and clinically challenging manifestation of XLP-1, with up to 65% of patients dying despite the use of chemoimmunotherapy (3) . Accordingly, alternative and more effective treatment strategies are sorely needed for XLP-1 patients who develop FIM.
T lymphocytes derived from XLP-1 patients exhibit multiple functional defects, including reduced cytotoxic activity (4) and impaired restimulation-induced cell death (RICD) (5) . RICD is a self-regulatory apoptosis program triggered by repeated T cell receptor (TCR) stimulation that maintains peripheral immune homeostasis by constraining the accumulation of activated T cells (6) . A similar death defect is present in the activated T cells of Sh2d1a −⁄− mice (7) . It is proposed that defective RICD, combined with impaired clearance of EBVinfected B cells, sustains and amplifies the expansion of activated T cells that typifies FIM (5, 6) .
SAP binds to immunotyrosine-based switch motifs within the cytoplasmic domains of the SLAM family receptors (SLAM-Rs) (8) , thus competing with the binding of SH2 domain-containing inhibitory lipid and tyrosine phosphatases such as SH2-containing inositol polyphosphate 5-phosphatase (SHIP) and SH2-containing protein tyrosine phosphatase 1 and 2 (SHP-1)/SHP-2 (9) . In addition, SAP facilitates recruitment of kinases such as FynT and Lck to SLAM-Rs to promote optimal signaling within T, NK, and NKT cells (10, 11) . Indeed, RICD resistance in XLP patient T cells results in part from weak TCR signaling associated with excess SHP-1 activity and defective recruitment of Lck to the NTB-A receptor, which colocalizes with the TCR (5, 11) . Although SAP links SLAM-R signaling to several downstream functions via activation of Src-family kinases [for example, interleukin-4 (IL-4) secretion (12) , iNKT cell development (13) ], this signaling axis is not the only pathway in which SAP is involved for signal regulation. For example, the requirement for SAP in the provision of CD4 + T cell-mediated "help" for B cell differentiation is Fyn-independent (14) . To fully understand XLP-1 pathogenesis and develop more effective therapeutic interventions, the mechanistic characterization of signaling molecules involved in these "alternative" SAP-dependent signaling pathways is imperative.
We recently observed that after TCR stimulation, SAP selectively inhibits diacylglycerol kinase a (DGKa) without requiring FynT or Lck (15) . DGKa and DGKz phosphorylate diacylglycerol (DAG) to generate phosphatidic acid, thereby modulating TCR signal strength by regulating DAG levels and downstream biochemical events (16, 17) . In activated T cells, silencing SAP expression results in persistently active DGKa and thus impaired DAG signaling, leading to reduced protein kinase Cq (PKCq) membrane recruitment, NFAT (nuclear factor of activated T cells) and ERK1/2 (extracellular signal-regulated kinase 1/2) activation, and IL-2 production (15) . These data collectively suggest that upon antigen stimulation, SAP inhibits DGKa activity to facilitate optimal DAG accumulation and full TCR signal strength, ultimately leading to cell activation.
Because TCR signal strength directly correlates with RICD sensitivity (18), we hypothesized that the reduced RICD of XLP-1 T cells might be linked to deregulation of DGKa in the absence of functional SAP. Consistent with this notion, we show herein that the loss of SAP in T cells results in reduced DAG polarization to the immune synapse (IS) and impaired TCR-induced DAG-dependent TCR signaling. Both of these events are due to persistent DGKa activity and contribute to RICD resistance. Consequently, the inhibition of DGKa in XLP-1 T cells restored DAG signaling and RICD by rescuing IS architecture and triggering a specific DAG-dependent apoptotic process mediated by the orphan nuclear receptors NR4A1 (NUR77) and NR4A3 (NOR1). Strikingly, in vivo inhibition of DGKa activity reduced the excessive CD8
+ T cell accumulation and interferon-g (IFNg) production that occur in Sh2d1a −⁄− mice infected with lymphocytic choriomeningitis virus (LCMV), a murine model of FIM. Our findings illuminate the SAP/ DGKa signaling axis as a key regulator of TCR-induced apoptosis. These results highlight DGKa as a novel, druggable target for treating FIM by promoting RICD, reducing the accumulation of pathogenic, activated CD8 + T cells, and thus mitigating the life-threatening immunopathology that often occurs in EBV-infected XLP-1 patients.
RESULTS

DGKa inhibition rescues RICD in SAP-deficient T cells
To investigate whether reduced DAG signaling contributes to the T cell-driven pathologic manifestations of XLP-1, we examined whether silencing or inhibition of DGKa could restore the sensitivity of XLP-1 T cells to RICD. SAP-deficient XLP-1 T cells exhibit reduced RICD relative to control T cells after stimulation with increasing concentrations of the agonistic anti-CD3 antibody (Ab) OKT3 (5) (Fig. 1, A and  B) . Remarkably, this defect in RICD was substantially rescued by the small interfering RNA (siRNA)-mediated silencing of DGKa (Fig. 1 , A to C) or by pretreatment with the DGKa inhibitor R59949 (Fig. 1,  D and E) or R59022 (Fig. 1F) (19) . The rescue in RICD obtained upon DGKa inhibition was likely due to the induction of apoptosis, as indicated by an increased percentage of AnnexinV + cells (Fig. 1G) . Conversely, the inhibition or silencing of DGKa had little effect on RICD in activated T cells from healthy subjects (Figs. 1 and 2) .
Because patient-derived cells were limited, we repeated these assays using siRNA to knock down SAP expression in activated T cells from healthy donors (Fig. 2) (5) . In agreement with our previous findings, SAP-silenced cells exhibited defective RICD that was rescued by concomitant silencing of DGKa (Fig. 2, A and B ) or by treatment with the DGKa inhibitor R59949 (Fig. 2C) or R59022 (Fig. 2D ). This restoration of RICD in SAP-silenced T cells was associated with enhanced apoptosis, as indicated by increased AnnexinV staining (Fig. 2E) . For other isoforms expressed in T cells, silencing of DGKz, but not DGKd, also partially rescued RICD in SAP-silenced cells ( fig. S1, A to D) . Conversely, overexpression of DGKa or DGKz conferred partial resistance to RICD in normal T cells (fig. S1, E and F). These findings suggest a link between the RICD resistance of SAP-deficient lymphocytes and unrestrained DAG depletion caused by enhanced DGK activity. To explore this further, we supplemented cultures with the DAG analog 1,2-dioctanoyl-sn-glycerol (C8-DAG), which is rapidly incorporated into the cell membrane and triggers DAG-dependent signaling (20) . Indeed, C8-DAG treatment markedly enhanced RICD in SAP-silenced but not control T cells (Fig. 2F) . Collectively, these data demonstrate that excessive DGKa activity contributes to RICD resistance in SAP-deficient T cells and that this process can be reversed by inhibition of DGKa. These data suggest that SAP promotes TCR signal strength and RICD sensitivity by attenuating DAG metabolism carried out by DGKa in activated T cells (Fig. 2G) .
Inhibition of DGKa rescues defective DAG polarization and signaling at the IS in SAP-deficient cells DAG generation and polarization at the IS are required for TCRinduced cellular responses (21) . To investigate whether the deregulated DGKa activity caused by SAP deficiency affects DAG polarization toward the IS, we imaged DAG localization using a PKCq-cysteinerich domain (CRD)-based biosensor (22) . After activation by superantigen-loaded Raji B cells, we observed that PKCq-CRD polarization to the IS was strongly reduced in SAP-silenced versus control Jurkat cells (Fig. 3, A to D) . In contrast, co-silencing of DGKa (Fig. 3, A and B) or pretreatment with the DGK inhibitor R59949 (Fig. 3 , C and D) restored PKCq-CRD polarization in SAP-silenced T cells. Consistent with the finding that DGKa shapes the DAG gradient at the IS (23), DAG polarization was also reduced in SAPexpressing, DGKa-silenced Jurkat cells (Fig. 3, A and B) .
Polarized DAG signaling triggers F-actin polymerization and microtubule organizing center (MTOC) orientation (24, 25) . Consistent with reduced DAG polarization, SAP-silenced T cells exhibited a strong defect in F-actin accumulation at, and MTOC orientation toward, the IS upon contact with superantigen-loaded Raji cells (Fig. 3 , E to J). Again, silencing or inhibition of DGKa partially restored these processes (Fig. 3 , E to J). These findings indicate that SAP regulates the architecture of the IS by inhibiting DGKa, thereby limiting DAG metabolism locally.
We next investigated whether inhibition of DGKa restores DAGmediated signaling downstream of the TCR in SAP-silenced primary human T cells. PKCq and RasGRP1 are recruited to the IS in a DAGdependent manner (26, 27) and are required for induction of RICD (28, 29) . Consistent with our hypothesis, SAP-silenced primary T cells exhibited defective recruitment of PKCq and RasGRP1 to the IS, which was fully restored upon DGKa silencing (Fig. 4, A, B , E, and F) or pharmacological inhibition (Fig. 4, C , D, G, and H). Considering inhibition of DGKa also rescues defective ERK1/2 activation in SAPdeficient T cells (15) , these data underscore the importance of the SAP/DGKa axis in regulating DAG-dependent signaling.
To test if inhibition of DGKa rescues RICD in SAP-deficient T cells by restoring specific DAG-mediated signaling pathways, we examined whether the rescue of RICD requires the activity of PKCq or RasGRP1. Silencing of PKCq (Fig. 5A) or RasGRP1 (Fig. 5B ) reduced RICD in control siRNA-transfected T cells and completely abrogated the rescue of RICD in SAP and DGKa siRNA-transfected cells. Moreover, pharmacological inhibition of PKC or MEK (mitogenactivated protein kinase)/ERK enzymatic activity also prevented the restoration of RICD noted after DGKa silencing in SAP-deficient T cells ( fig. S2) .
TCR activation stimulates DAG-dependent induction of IL-2 and the high-affinity IL-2 receptor CD25 (30, 31) , which are both required for RICD (32) . Indeed, inhibition or silencing of DGKa restored induction of CD25 in SAP-silenced T cells after TCR restimulation, and a similar trend was observed with IL-2 expression (Fig. 5, C to E). These findings further establish the SAP/DGKa axis as a critical regulator of DAG signaling potency. Collectively, these findings underscore the vital role of SAP-dependent inhibition of DGKa in sustaining DAG signaling, leading to the activation of PKCq and Ras-ERK and RICD (Fig. 5F ).
NUR77 and NOR1 mediate the rescue of RICD that is induced by DGKa inhibition in SAP-deficient T cells We next investigated the mechanism by which the enhancement of DAG signaling obtained after inhibition of DGKa restores RICD sensitivity in SAP-deficient T cells. We previously showed that in SAP-deficient T cells, TCR-induced expression of key proapoptotic genes such as FASLG and BCL2L11 is impaired (5). We observed that silencing or inhibition of DGKa failed to rescue FASLG or BCL2L11 expression after TCR restimulation of SAP-silenced T cells ( fig. S3, A  and B) . Similarly, DGKa blockade failed to restore the induction of all three major isoforms of BIM protein (extra long, EL; long, L; and short, S), as well as full-length and soluble FASL protein in SAP-silenced and XLP-1 patient T cells after restimulation (fig. S3, C to E). These observations imply that DGKa inhibition does not restore all SAP-dependent, proapoptotic effector functions that contribute to RICD sensitivity.
Instead, we found that SAP-deficient T cells exhibit a previously unrecognized defect in TCR restimulation-induced upregulation of NR4A1 (NUR77) and NR4A3 (NOR1), two nuclear receptors involved in negative selection of thymocytes and RICD of mature T cells (33) . DGKa silencing or inhibition selectively restored TCR-dependent induction of both NR4A1 and NR4A3 in SAP-silenced activated T cells (Fig. 6, A to D) . DGKa inhibition also partially rescued NUR77 and NOR1 protein induction in XLP-1 T cells after TCR restimulation (Fig. 6E) . Upon TCR engagement, NUR77 and NOR1 proteins are phosphorylated by the ERK1/2-regulated 90-kD ribosomal S6 kinase (RSK), triggering the intrinsic apoptosis pathway (34) . Indeed, the RSKspecific inhibitor SL0101 (35) significantly reduced RICD in control T cells, confirming that phosphorylation of NUR77 and NOR1 is an important component of RICD execution (Fig. 6, F to H) . SL0101 significantly blunted the RICD rescue triggered by DGKa inhibition in XLP-1 T cells, as well as in SAP/DGKa-silenced T cells (Fig. 6, F to H) . These data indicate that the rescue of RICD afforded by DGKa blockade in SAPdeficient T cells is dependent on RSK activity. Moreover, concomitant knockdown of NUR77 and NOR1 reduced the rescue of RICD induced by DGKa inhibition in XLP-1 T cells (Fig. 6, I to K). Together, these observations indicate that inhibition of DGKa boosts RICD in SAPdeficient T cells in part by selectively restoring TCR-induced up-regulation and RSK-dependent phosphorylation of NUR77 and NOR1 (Fig. 6L) .
DGKa inhibition reduces CD8
+ T cell accumulation and activation in LCMV-infected Sh2d1a −⁄− mice Defective RICD is thought to contribute to the aberrant T cell activation and accumulation that occur in EBV-infected XLP-1 patients (36) . The demonstration that DGKa silencing or inhibition sensitizes SAP-deficient lymphocytes to RICD in vitro prompted us to assess whether DGKa inhibition might influence T cell-mediated immunopathology in vivo. Toward this end, we used a murine model in which Sh2d1a −⁄− mice are infected with LCMV. In this model, Sh2d1a
−⁄− mice develop many of the cardinal manifestations of FIM, including CD8 + T cell expansion, proinflammatory cytokine production, and tissue infiltration (37, 38) . For these experiments, wild-type (Sh2d1a
−⁄− mice were infected with LCMV Armstrong and 4 days later were treated with vehicle or R59022 (39). On day 8, the peak of the antiviral T cell response, mice were euthanized and evaluated for hyperinflammation.
After LCMV infection, both wild-type and Sh2d1a −⁄− mice developed marked and comparable splenomegaly (Fig. 7, A and B ) that was associated with an increase in the absolute number of total splenocytes (Fig. 7C) . Examination of splenocyte immunophenotype revealed a significant increase in the percentage and absolute number of total as well as LCMV-specific (gp33 + ) CD8 + T cells, most of which exhibited an activated CD44 + phenotype (Fig. 7, D to I) . Treatment of LCMV-infected wild-type mice with R59022 did not significantly affect any of these parameters (Fig. 7) . Conversely, R59022 treatment of LCMV-infected Sh2d1a −⁄− mice appeared to lessen organomegaly (Fig.  7, A and B) and decrease the total splenic lymphocyte count (Fig. 7C) . Although R59022 treatment did not affect the percentage of activated splenic CD8 + T cells in either mouse strain, it did induce a significant (100 ng/ml). Cell lysates were analyzed by Western blotting for NUR77, NOR1, and b-actin content. Data are representative of two independent experiments using different donors. (F and G) Activated T cells from normal donors (Ctrl) or XLP-1 patients were pretreated for 30 min with DMSO, SL0101 (90 mM), R59949 (10 mM), or both, followed by restimulation with OKT3 (100 ng/ml). After 24 hours, % cell loss was evaluated by PI staining. Data are means ± SD of one experiment each performed in triplicate using different donors. (H) Activated donor T cells were transfected with the indicated siRNA and treated 4 days later with SL0101 (50 mM) for 30 min, followed by OKT3 (10 ng/ml). After 24 hours, % cell loss was evaluated by PI staining. Data are means ± SEM of five experiments performed in triplicate. (I and J) Activated T cells from normal donors (Ctrl) or XLP-1 patients were transfected control or NUR77 + NOR1 siRNA and treated 4 days later with DMSO or R59022 (10 mM) for 30 min, followed by OKT3 (100 ng/ml). After 24 hours, % cell loss was evaluated by PI staining. Data are means ± SD of one experiment each, performed in triplicate using different donors. Asterisks in all panels denote statistical significance by two-way ANOVA with Sidak correction. decrease in the number of total as well as LCMV-specific CD8 + T cells selectively in the Sh2d1a −⁄− animals (Fig. 7, D 
to I). Compared to wild-type animals, LCMV-infected Sh2d1a
−⁄− mice also exhibited a trend toward higher serum IFNg levels (Fig. 8A ) and greater degrees of tissue inflammation (Fig. 8, B to D) . To evaluate whether DGKa inhibition affected CD8 + T cell functions such as cytokine production or degranulation, splenocytes from LCMV-infected or uninfected, R59022 treated or untreated mice were cultured directly ex vivo with the major histocompatibility complex (MHC) class I-restricted LCMV peptide gp33 and examined for expression of intracellular TNFa (tumor necrosis factor-a), IFNg, and surface CD107a. R59022 treatment did not affect the percentage of CD8 + T cells that secreted cytokines (TNFa or IFNg) or degranulated (CD107a exposure) in LCMV-infected wild-type or Sh2d1a −⁄− mice (Fig. 8, E and F) . R59022 treatment actually enhanced the cytolytic activity of Sh2d1a −⁄− CD8 + T cells against autologous B cell targets in vitro ( fig. S5) . However, such treatment did reduce the absolute number of cytokine-producing and degranulating cells only in the Sh2d1a −⁄− animals (Fig. 8G) . Consistent with these findings, only R59022-treated Sh2d1a −⁄− mice exhibited a significant reduction in the serum IFNg levels (Fig. 8A) . Finally, R59022 treatment significantly reduced the number and size of hepatic inflammatory infiltrates in LCMV-infected Sh2d1a −⁄− but not wild-type mice (Fig. 8, B to D) . These findings collectively indicate that inhibition of DGKa selectively decreases the magnitude of the CD8 + T cell effector pool in LCMV-infected Sh2d1a −⁄ − mice. DGKa inhibition had no adverse effects on viral clearance, as LCMV was efficiently cleared from wild-type and Sh2d1a −⁄ − mice by day 8 with or without R59022 treatment ( fig. S6 ). These preclinical data suggest that pharmacologic inhibition of DGKa might reduce the accumulation of aberrantly activated CD8 + T cells and subsequent hypercytokinemia and tissue inflammation that occur in EBV-infected XLP-1 patients, without impairing CD8 + T cell activity or viral clearance.
One major limitation of this study is its focus on the role of the SAP/DGKa axis strictly in T cells. It does not address the putative role of DGKa in other SAP-deficient immune cells such as NK or NKT cells, which also likely contribute to the development of various XLP-1 manifestations. In addition, although LCMV infection of Sh2d1a −⁄− mice is a widely used murine model of FIM, it does not fully recapitulate the pathogenesis of EBV infection in humans. Finally, the translation of these findings to the clinic will require the development and characterization of novel, clinical-grade DGKa-specific inhibitors. Nonetheless, our data clearly provide proof of concept that DGKa may be a novel drug target for treating XLP-1-associated FIM.
DISCUSSION
Our results demonstrate that inhibition of DGKa restores sensitivity to RICD in SAP-deficient T cells and reduces hyperinflammation in LCMV-infected Sh2d1a −⁄− mice. These data support the hypothesis that in SAP-deficient T cells, persistent DGKa activity increases DAG metabolism at the IS, thus reducing DAG signaling and RICD sensitivity, and underscore the role of SAP in modulating DGKa activity (15) . In SAP-expressing T cells, further inhibition of DGKa only marginally influenced sensitivity to RICD in vitro and did not dampen the LCMV-induced CD8 + T cell response of wild-type mice in vivo. Our finding that inhibition of DGKa restores proper IS organization in SAP-deficient T cells indicates that SAP, through regulation of DGKa, controls DAG polarization at the IS, thus promoting F-actin polymerization and MTOC orientation. Indeed, DGKa is recruited to the peripheral SMAC (pSMAC), where it shapes the DAG gradient responsible for the recruitment of novel PKC isoforms (e, h, and q), which control MTOC polarization and actin polymerization (Fig. 3) (23, 25) . DGKa inhibition also partially rescued impaired cytolytic activity in SAP-deficient cytotoxic T lymphocytes (CTLs) ( fig. S5) , further highlighting the link between SAP-dependent inhibition of DGKa and IS function (4) . Together, these data indicate that SAP-mediated negative regulation of DGKa controls IS structural organization and function by regulating the TCR-induced gradient of DAG.
Both DGKa and DGKz regulate TCR-induced DAG signaling (16, 17) . Consistently, inhibition or overexpression of either isoform rendered T cells more or less sensitive to RICD, respectively, confirming that both isoforms regulate DAG signalling in this context ( fig. S1 ). Accordingly, administration of exogenous DAG partially rescued the defective RICD in SAP-deficient T cells (Fig. 2F) . However, only DGKa is regulated by SAP and shapes the DAG gradient at the IS (15, 23) . We speculate that DGKa, which colocalizes with F-actin at the pSMAC, regulates the DAG gradient and F-actin polymerization at the IS, whereas DGKz, which is more evenly distributed in the IS, metabolizes most of the DAG generated there, consistent with proposed models (23, 40) . Notably, silencing of DGKd, which is highly expressed in T cells, did not affect RICD, underscoring the specific roles of DGKa and DGKz in regulating the DAG pool relevant for signaling and RICD onset.
Our finding that inhibition of DGKa restored RasGRP1 and PKCq recruitment to the IS in SAP-deficient T cells, and subsequent DAGdependent induction of IL-2 and CD25, illuminates a biochemical link between the SAP/DGKa axis, IS restoration, and downstream signaling events required for RICD (28) (29) (30) (31) . Indeed, activation of RasGRP1 and PKCq was required to rescue RICD in SAP-deficient T cells upon DGKa blockade (Fig. 5, A and B, and fig. S2 ). DGKa inhibition cannot recapitulate all SAP-dependent signaling functions, such as TCR-induced expression of FASLG or BCL2L11, genes previously implicated in SAP-associated induction of RICD (5). This observation suggests that rescue of DAG-mediated signaling activates other proapoptotic pathways that partially compensate to boost RICD sensitivity. Here, we show that the induction of NUR77 and NOR1 is defective in TCR-restimulated SAP-deficient T cells, and that the expression of these genes is restored by inhibition of DGKa. NUR77 and NOR1 are orphan nuclear receptors known to trigger thymocyte apoptosis during negative selection and mediate RICD (33, 41) . The proapoptotic activity of NUR77 and NOR1 depends on their phosphorylation by RSK, an ERK1/2-dependent kinase, and subsequent translocation to the mitochondria to promote mitochondrial depolarization and apoptosis (33, 34) . We observed that ERK and RSK activity, as well as NUR77 and NOR1, were required for RICD rescue triggered by DGKa inhibition in XLP-1 T cells. These observations provide a mechanistic connection between the rescue of DAG signaling and the execution of RICD.
EBV-induced FIM is proposed to result from defective RICD of CD8 + T cells and impaired cytotoxic elimination of EBV-infected B cells by CD8 + T cells and NK cells. These events contribute to the excessive accumulation of activated effector CD8 + T cells and lifethreatening damage to the liver, the bone marrow, and other organs (2, 5) . Using a murine model of FIM (37, 38), we showed that DGKa ) from PBS (P), LCMV-infected (L), and LCMV-infected mice with R59022 treatment (L + R) groups were left unstimulated or stimulated with gp33 peptide (0.4 ng/ml) in the presence of monensin (1000 mg/ml) for 5 hours. Cells were then analyzed for intracellular cytokine production and degranulation. mice, leading to fewer and smaller lymphocytic infiltrates within the liver and marked reductions in the level of IFNg in the serum. These results suggest that RICD resistance is connected to aberrant DGKa activity and serves as a key driver of virus-induced immunopathology in Sh2d1a −⁄− mice. Remarkably, the apoptosis resistance of activated T cells in LCMV-infected Sh2d1a −⁄− mice can be overcome via DGKa inhibition, even when such inhibition is initiated well after infection is established. These data are relevant to the clinical setting, where patients often present with FIM days to weeks after primary EBV infection.
In conclusion, our findings underscore the importance of SAPmediated DGKa inhibition in maintaining lymphocyte homeostasis by ensuring sufficient TCR-induced DAG signaling strength for apoptosis. These data provide proof of principle that treatment with a DGKa inhibitor could serve as a novel, reasonable strategy to counteract pathological EBV-driven lymphohistiocytosis that occurs in EBV-infected XLP-1 patients by restoring the RICD sensitivity of activated CD8 + T cells.
MATERIALS AND METHODS
Study design
This was a preclinical study to (i) determine if DGKa inhibition could rescue RICD in SAP-deficient T cells and (ii) assess the efficacy of a DGKa inhibitor in attenuating CD8 + T cell lymphocytosis and immunopathology in LCMV-infected SAP-deficient mice, a model of FIM. Although in vitro experiments utilizing XLP-1 patient T cells were often constrained by limited sample availability, each RICD experiment was performed with at least two separate XLP patients and different control donors (for example, Fig. 1, A and B) . We also generated robust corroborating data using siRNA-mediated SAP knockdown in T cells from multiple human donors (n ≥ 3 experiments each). Once we established that DGKa blockade restored RICD sensitivity in SAP-deficient T cells, we focused on delineating the biochemical mechanism that explains this phenomenon. For all in vitro data, the number of experiments (including technical replicates) is defined in each figure legend. For in vivo experiments, numbers of mice are outlined in each figure legend. All statistical analyses described below were verified by consultation with an experienced biostatistician [C. Olsen, Uniformed Services University of the Health Sciences (USUHS)].
Cell culture
Peripheral blood mononuclear cells (PBMCs) were isolated from normal controls or XLP-1 patients by Ficoll-Paque PLUS (GE Healthcare) density gradient centrifugation, washed, and resuspended at 2 × 10 6 cell/ml in complete media (cRPMI): RPMI-GlutaMAX (Life Technologies) containing 10% heat-inactivated fetal calf serum (FCS) (Lonza), 2 mM glutamine, and penicillin and streptomycin (100 U/ml) (Life Technologies). T cells were activated with anti-CD3 (1 mg/ml) (clone UCHT1) and anti-CD28 (clone CD28.2) antibodies. After 3 days, activated T cells were washed and cultured in cRPMI plus recombinant human IL-2 (rhIL-2) (100 IU/ml) (PeproTech) at 1.2 × 10 6 cells/ml for ≥7 days before apoptosis assays were conducted (media changed every 2 to 3 days).
Jurkat A3 cells were from American Type Culture Collection, and 293FT from Life Technologies. Cells were cultured in RPMI or Dulbecco's modified Eagle's medium (Life Technologies) with 10% FCS and antibiotics/antimycotics (Sigma-Aldrich).
DGK inhibitors R59949 and R59022 (Sigma-Aldrich) were dissolved in DMSO. All reagents and antibodies used are listed in table S1. Immunofluorescence experiments with primary T cells Human T cells were stimulated with soluble anti-CD3 and anti-CD28 (1 mg/ml) for at least 7 days and transfected with Amaxa Nucleofector Kit for human T cells (Lonza) with control, SAP-specific, and/or DGKa-specific siRNA. After 72 hours, T cells were incubated with Raji B cells loaded with mixed SEE (staphylococcal enterotoxin E) and SEB (staphylococcal enterotoxin B) superantigens (1 mg/ml) for 15 min, fixed, and stained for either PKCq or RasGRP1. For some experiments, transfected T cells were pretreated with R59949 (10 mM, 30 min, 37°C) or DMSO before conjugation.
Cytofluorimetry
To examine RICD, activated T cells (10 5 cells per well) were plated in triplicate in 96-well round-bottom plates and treated with anti-CD3e mAb (monoclonal antibody) OKT3 (1 to 100 ng/ml) in cRPMI + rhIL-2 (100 IU/ml) for 24 hours. R59949 (5 to 10 mM), R59022 (5 to 10 mM), DAG (50 mM), U0126 (5 mM), FR180204 (10 mM), or Rottlerin (6 mM) inhibitors were added 30 min before restimulation. At 24 hours after restimulation, cells were stained with PI (1 mg/ml) and collected for For AnnexinV assays,~1 × 10 6 cells were treated with OKT3 (10 ng/ml) as above. Cells were stained 6 to 12 hours later with AnnexinV-phycoerythrin (BioLegend) and analyzed on Accuri C6.
To evaluate CD25 expression, 1 × 10 6 cells were stimulated with OKT3 (100 ng/ml) for 24 hours and fixed and stained with anti-CD25 plus anti-mouse Alexa Flour 488. Stained cells were collected on a FACSCalibur.
Western blotting
Lymphocytes (1 × 10 6 to 10 × 10 6 cells) were stimulated, lysed, and subjected to SDS-polyacrylamide gel electrophoresis and immunoblotting as described (5, 15) . Immunoblot images were acquired and quantified using a Versadoc Model 4000 Imaging System (Bio-Rad) or ImageJ software (for film). Spot densitometry analyses are summarized in table S4.
Quantitative RT-PCR Activated lymphocytes (30 × 10 6 cell/ml) were stimulated in cRPMI with OKT3 (10 mg/ml) for 4 hours. R59949 (5 mM) was added 30 min before restimulation. Cells were washed with cold PBS, and mRNA was extracted using a ChargeSwitch Total RNA Cell Kit (Life Technologies). RNA was reverse-transcribed using High-Capacity cDNA Reverse Transcription Kits (Life Technologies), and cDNA targets were quantified by RT-PCR (C1000 Thermal Cycler CFX96, BioRad) using TaqMan gene expression assays (see table S3), with GUSB as the housekeeping control (Life Technologies).
Mice and in vivo experiments
Sh2d1a
−/− mice were as described (38) . C57BL/6 (B6) mice were purchased from Jackson Laboratories. To establish LCMV infection, mice received 2 × 10 5 plaque-forming units of LCMV Armstrong by intraperitoneal injection on day 0, and experiments were carried out until day +8 after infection. Beginning at day 4, mice were given twice daily intraperitoneal injections of R59022 at a dose of 2 mg/kg body weight, dissolved in DMSO. Mice in all groups were sex-and age-matched. Stimulation of mouse splenocytes in vitro, assessment of liver histology, and quantification of viral titers were performed as described in the Supplementary Methods.
Statistical analysis
Evaluation of in vitro assays across multiple treatments (RICD, RT-PCR, and ELISA), and in vivo experiments was analyzed using twoway ANOVA (a = 0.05) with Sidak's multiple comparisons correction using GraphPad PRISM software. When comparing two groups (RT-PCR, AnnexinV + cells), a two-tailed paired Student's t test was performed in Microsoft Excel. Error bars are described in the figure legends as ± SEM or ± SD where appropriate. Asterisks denote significance in all experiments; P values are included in table S5. Table S1 . Reagents. Table S2 . siRNA sequences. Table S3 . TaqMan gene expression arrays. Table S4 . Spot densitometry analysis for Western blotting. Table S5 . Statistical analyses. Unmodified Western blot images. Source data (excel).
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